Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
Front Immunol ; 11: 1933, 2020.
Article in English | MEDLINE | ID: mdl-33072067

ABSTRACT

Background: Limited treatment strategies are available for squamous-cell lung cancer (SQLC) patients. Few studies have addressed whether immune-related genes (IRGs) or the tumor immune microenvironment can predict the prognosis for SQLC patients. Our study aimed to construct a signature predict prognosis for SQLC patients based on IRGs. Methods: We constructed and validated a signature from SQLC patients in The Cancer Genome Atlas (TCGA) using bioinformatics analysis. The underlying mechanisms of the signature were also explored with immune cells and mutation profiles. Results: A total of 464 eligible SQLC patients from TCGA dataset were enrolled and were randomly divided into the training cohort (n = 232) and the testing cohort (n = 232). Eight differentially expressed IRGs were identified and applied to construct the immune signature in the training cohort. The signature showed a significant difference in overall survival (OS) between low-risk and high-risk cohorts (P < 0.001), with an area under the curve of 0.76. The predictive capability was verified with the testing and total cohorts. Multivariate analysis revealed that the 8-IRG signature served as an independent prognostic factor for OS in SQLC patients. Naive B cells, resting memory CD4 T cells, follicular helper T cells, and M2 macrophages were found to significantly associate with OS. There was no statistical difference in terms of tumor mutational burden between the high-risk and low-risk cohorts. Conclusion: Our study constructed and validated an 8-IRG signature prognostic model that predicts clinical outcomes for SQLC patients. However, this signature model needs further validation with a larger number of patients.


Subject(s)
Biomarkers, Tumor/genetics , Carcinoma, Squamous Cell/genetics , Gene Expression Profiling , Lung Neoplasms/genetics , Transcriptome , Aged , Carcinoma, Squamous Cell/immunology , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/therapy , Databases, Genetic , Female , Humans , Lung Neoplasms/immunology , Lung Neoplasms/mortality , Lung Neoplasms/therapy , Male , Middle Aged , Mutation , Predictive Value of Tests , Prognosis , Reproducibility of Results , Risk Assessment , Risk Factors , Tumor Microenvironment
2.
Front Cell Dev Biol ; 8: 609285, 2020.
Article in English | MEDLINE | ID: mdl-33520990

ABSTRACT

Cisplatin (DDP) is the first-line chemotherapeutic agent against lung cancer. However, the therapeutic effect of DDP loses over time due to the acquired drug resistance in non-small cell lung cancer (NSCLC) cells. In recent years, the role of the traditional Chinese medicine (TCM) cordycepin (Cor) in cancer treatment has been attracting attention. However, the effects of Cor on DDP resistance in NSCLC are unclear. In the present study, we aimed to investigate the effects of Cor in combination with DDP on cell proliferation and apoptosis in NSCLC and explore possible underlying mechanisms. The cell proliferation and apoptosis were analyzed in NSCLC parental (A549) and DDP-resistant (A549DDP) cells treated with DDP alone or in combination with Cor both in vitro and in vivo. Different genes and signaling pathways were investigated between DDP-sensitive and DDP-resistant A549 cells by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. The perturbations of the MAPK and PI3K-AKT signaling pathways were evaluated by Western blot analysis. Our data showed that Cor markedly enhanced DDP inhibition on cell proliferation and promotion of apoptosis compared to the DDP-alone group in both A549 and A549DDP cells. The synergic actions were associated with activation of AMPK; inhibition of AKT, mTOR, and downstream P709S6K; and S6 phosphorylation in the AKT pathway compared with DDP alone. Collectively, combination of Cor and DDP has a synergistic effect in inhibiting proliferation and promoting apoptosis of NSCLC cells in the presence or absence of DDP resistance. The antitumor activity is associated with activation of AMPK and inhibition of the AKT pathway to enhance DDP inhibition on NSCLC. Our results suggested that Cor in combination with DDP could be an additional therapeutic option for the treatment of DDP-resistant NSCLC.

3.
Int J Biol Macromol ; 91: 905-10, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27208798

ABSTRACT

The weight-loaded swimming capability, tumor growth, survival time and biochemical markers of Ganoderma lucidum polysaccharides (GLPs) in a chemotherapy-related fatigue mouse model were tested in the present study. The results showed that the middle-dose GLPs (GLP-M) and the high-dose GLPs (GLP-H) could increase the exhausting swimming time, which was observed to decrease in the cisplatin control group(PCG) and the tumor control group (TCG).The GLP-M and the GLP-H had reduced serum levels of tumor necrosis factor-αand interleukin-6, which were up-regulated by cisplatin. Cisplatin and the presence of tumor significantly enhanced the malondialdehyde (MDA) content and inhibited the activity of superoxide dismutase (SOD) in the muscle. Administration of GLPs at a high dose decreased the levels of MDA and up-regulated the SOD activity. The high-dose GLPs+cisplatin group presented a decreased tendency of tumor volume and a lower tumor weight compared with PCG. Moreover, the mice in the GLP-M and GLP-H groups had longer survival times compared with the mice in the TCG and PCG.The levels of creatinine and serum blood urea nitrogen, which are up-regulated by cisplatin, were significantly reduced by GLP-M and GLP-H. Therefore, these results suggest that GLPs might improve chemotherapy-related fatigue via regulation of inflammatory responses, oxidative stress and reduction of nephrotoxicity.


Subject(s)
Drug Therapy , Fatigue/chemically induced , Fatigue/drug therapy , Polysaccharides/therapeutic use , Reishi/chemistry , A549 Cells , Animals , Blood Urea Nitrogen , Cisplatin/adverse effects , Creatinine/blood , Fatigue/blood , Interleukin-1beta/blood , Interleukin-6/blood , Male , Malondialdehyde/metabolism , Mice, Inbred BALB C , Muscle, Skeletal/drug effects , Muscle, Skeletal/enzymology , Superoxide Dismutase/metabolism , Survival Analysis , Swimming , Transforming Growth Factor alpha/blood , Tumor Burden/drug effects
4.
Space Med Med Eng (Beijing) ; 16(5): 371-3, 2003 Oct.
Article in Chinese | MEDLINE | ID: mdl-14753239

ABSTRACT

OBJECTIVE: To measure the oxygen saturation of blood in rat's brain non-invasively after acceleration with near infrared spectroscopy technique. METHOD: A serious of model about different ischemia and hypoxia of head, measured oxygen saturation by phlebotomize were made, and the difference with normal group was obtained. Its absorption intensity was measured and a curve showing the difference between the normal value was drawn. According to the curve, cerebral blood oxygen saturation after acceleration was calculated with the measured absorption intensity after high or push-pull maneuver by near infrared spectroscopy. RESULT: Compared high +Gz and push pull effect group with 0 Gz group, the content of ox hemoglobin reduced, in opposition the deox hemoglobin increased, the greater the difference, the lower the content of oxygen saturation of blood. CONCLUSION: Oxygen saturation of blood in the rat's brain can be obtained non-invasively with near infrared spectroscopy.


Subject(s)
Hypergravity/adverse effects , Hypoxia, Brain/blood , Oxygen/blood , Oxyhemoglobins/analysis , Spectroscopy, Near-Infrared , Acceleration , Animals , Brain Chemistry , Hypoxia, Brain/etiology , Hypoxia, Brain/metabolism , Models, Animal , Oxygen/metabolism , Oxyhemoglobins/metabolism , Rats , Unconsciousness/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...